PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary OpGen Announces Argus® Optical Mapping System Purchase by BGI
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 Gaithersburg, Md.—February 8, 2011—OpGen, Inc., a genomics and DNA analysis company and exclusive provider of optical mapping technology, today announced that BGI, the largest genomics organization in the world, purchased an Argus
View HTML
Toggle Summary OpGen Announces Argus® Optical Mapping System Purchase by Wellcome Trust Sanger Institute - See more at: http://opgen.com/news/press-releases#sthash.IZ7mrxlV.dpuf
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 Gaithersburg, Md.—January 6, 2011—OpGen, Inc. a commercial phase genomics and DNA analysis company, today announced that the Wellcome Trust Sanger Institute has purchased an Argus ™ Optical Mapping System in order to reduce the
View HTML
Toggle Summary OpGen, Inc., to Present at the Piper Jaffray 22nd Annual Health Care Conference
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 OpGen, Inc., to Present at the Piper Jaffray 22nd Annual Health Care Conference Gaithersburg, Md. – November 30, 2010 – OpGen, Inc. a commercial phase genomics company, today announced that Douglas White, chief executive officer,
View HTML
Toggle Summary BGI and OpGen Collaborate on Use of Optical Mapping for Whole Genome Assembly - See more at: http://opgen.com/news/press-releases#sthash.IZ7mrxlV.dpuf
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 Gaithersburg, Md. – November 4, 2010 – BGI, the largest genomics organization in the world, and OpGen, Inc., a commercial phase genomics company and exclusive provider of Optical Mapping Technology, announced their joint effort to
View HTML
Toggle Summary OpGen Completes $17 Million Series B Financing
Names Evan Jones as Executive Chairman of the Board Media Contac t: Dan Budwick Pure Communications, Inc. (973) 271-6085 Gaithersburg, Md. – September 27, 2010 – OpGen, Inc., a commercial phase genomics company, today announced the successful completion of a $17 million Series B equity financing.
View HTML